James N. Arvesen is president of the consulting firm Strategic Solutions and Services, Inc.
In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK ...
Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery. Do you know ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...
Distinct GLP1R and GIPR variants correlated with nausea/vomiting risk, with a GIPR signal appearing tirzepatide-specific and showing markedly increased vomiting odds. New studies from 23andMe suggest ...
The U.S. government awarded Shionogi Inc. a contract worth up to $482 million to expand domestic manufacturing of Fetroja ...
MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.
In this episode of Pharmaceutical Executive’s podcast series Leading Edge With Ken Banta, The Vanguard Network founder and ...
In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results